Motor deficits and neurofibromatosis type 1 (NF1)-associated MRI impairments in a mouse model of NF1

NMR in Biomedicine

Volumn 23, Issue 10, 2010, Pages 1173-1180

  Robinson, Ari ^a   Kloog, Yoel ^a   Stein, Reuven ^a   Assaf, Yaniv ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Motor; Mouse model; Neurofibromatosis type 1; Neurofibromin; T2 weighted MRI

Indexed keywords

BASAL GANGLIA; BRAIN REGIONS; COGNITIVE DEFICITS; CORRELATION ANALYSIS; GENETIC DISORDERS; MOTOR DEFICITS; MOTOR PATHWAY; MOTOR PERFORMANCE; MOUSE MODELS; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMIN; OPTIC TRACT; T2 RELAXATION; T2-WEIGHTED MRI; WHITE MATTER; WILD TYPES;

BRAIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN REGION; CEREBRAL PEDUNCLE; CONTROLLED STUDY; FEMALE; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC TRACT; PRIORITY JOURNAL; THALAMUS; WHITE MATTER; WILD TYPE;

MUS;

EID: 78650260684     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1546     Document Type: Article

References (39)

1. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009; 123: 124-133.
2. North K. Neurofibromatosis type 1. Am. J. Med. Genet. 2000; 97: 119-127.
3. Koth CW, Cutting LE, Denckla MB. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol. 2000; 6: 185-194.
4. Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am. J. Med. Genet. 1999; 89: 45-52.
5. Schrimsher GW, Billingsley RL, Slopis JM, Moore BD, 3rd. Visual-spatial performance deficits in children with neurofibromatosis type-1. Am. J. Med. Genet. A. 2003; 120: 326-330.
6. Brewer VR, Moore BD 3rd, Hiscock M. Learning disability subtypes in children with neurofibromatosis. J. Learn. Disabil. 1997; 30: 521-533.
7. Moore BD 3rd, Ater JL, Needle MN, Slopis J, Copeland DR. Neuropsychological profile of children with neurofibromatosis, brain tumor, or both. J. Child Neurol. 1994; 9: 368-377.
8. North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P, McHugh K, de Silva M. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology. 1994; 44: 878-883.
9. Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJ, Huijbregts SC. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychol. 2009; 23: 50-60.
10. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neurofibromatosis type 1. Semin. Pediatr. Neurol. 2006; 13: 8-20.
11. Hyman SL, Gill DS, Shores EA, Steinberg A, Joy P, Gibikote SV, North KN. Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology. 2003; 60: 1139-1145.
12. Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J. Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology. 2003; 61: 1725-1728.
13. Goh WH, Khong PL, Leung CS, Wong VC. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. J. Child Neurol. 2004; 19: 853-858.
14. Denckla MB, Hofman K, Mazzocco MM, Melhem E, Reiss AL, Bryan RN, Harris EL, Lee J, Cox CS, Schuerholz LJ. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am. J. Med. Genet. 1996; 67: 98-102.
15. Hyman SL, Gill DS, Shores EA, Steinberg A, North KN. T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J. Neurol. Neurosurg. Psychiatry. 2007; 78: 1088-1091.
16. Bawden H, Dooley J, Buckley D, Camfield P, Gordon K, Riding M, Llewellyn G. MRI and nonverbal cognitive deficits in children with neurofibromatosis 1. J. Clin. Exp. Neuropsychol. 1996; 18: 784-792.
17. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology. 1996; 46: 1660-1668.
18. Legius E, Descheemaeker MJ, Steyaert J, Spaepen A, Vlietinck R, Casaer P, Demaerel P, Fryns JP. Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. J. Neurol. Neurosurg. Psychiatry. 1995; 59: 638-640.
19. Rubin JB, Gutmann DH. Neurofibromatosis type 1 - a model for nervous system tumour formation? Nat. Rev. Cancer. 2005; 5: 557-564.
20. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990; 63: 843-849.
21. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-715.
22. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992; 69: 265-273.
23. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 1994; 7: 353-361.
24. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176.
25. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002; 22: 5100-5113.
26. Guo HF, Tong J, Hannan F, Luo L, Zhong Y. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature. 2000; 403: 895-898.
27. Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nurnberg P. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum. Mol. Genet. 1998; 7: 1261-1268.
28. Silva AJ, Frankland PW, Marowitz Z, Friedman E, Lazlo G, Cioffi D, Jacks T, Bourtchuladze R. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat. Genet. 1997; 15: 281-284.
29. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002; 415: 526-530.
30. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005; 15: 1961-1967.
31. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell. 2008; 135: 549-560.
32. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994; 8: 1019-1029.
33. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. Academic Press: San Diego, 2001.
34. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000; 11: 805-821.
35. Crum WR, Griffin LD, Hill DL, Hawkes DJ. Zen and the art of medical image registration: correspondence, homology, and quality. Neuroimage. 2003; 20: 1425-1437.
36. Rosenbaum T, Engelbrecht V, Krolls W, van Dorsten FA, Hoehn-Berlage M, Lenard HG. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev. 1999; 21: 268-273.
37. Holstege G, Bandler R, Saper CB. The emotional motor system. Prog. Brain Res. 1996; 107: 3-6.
38. Pell GS, Briellmann RS, Waites AB, Abbott DF, Jackson GD. Voxel-based relaxometry: a new approach for analysis of T2 relaxometry changes in epilepsy. Neuroimage. 2004; 21: 707-713.
39. Hendry J, DeVito T, Gelman N, Densmore M, Rajakumar N, Pavlosky W, Williamson PC, Thompson PM, Drost DJ, Nicolson R. White matter abnormalities in autism detected through transverse relaxation time imaging. Neuroimage 2006; 29: 1049-1057.